Barbara Kosacz is a partner in the Business department of Cooley Godward Kronish's Palo Alto office, and the national head of the Firm's Life Sciences practice. Ms. Kosacz has nearly 20 years of experience in counseling clients in the Life Sciences arena. Her clients range from early-stage start ups to large public companies. Ms. Kosacz advises clients on a variety of legal and business issues. Her particular expertise is in complex strategic partnering and joint venture transactions. She also represents both companies and investors and investment banks in private financings, spin-outs, public offerings, and M&A. Some of Ms. Kosacz' recent transactions include Medivation's collaboration with Pfizer for the worldwide development and commercialization of dimebon for Alzheimer's disease, the sale of Ilypsa to Amgen and subsequent spin out of Relypsa from Amgen, Aspreva's novel collaboration with Roche on the development and commercialization of Cellcept® in autoimmune diseases, and ChemoCentrx's $1.5B chemokine drug discovery and development collaboration with GlaxoSmithKline.
Ms. Kosacz is known for working closely with her clients as an integral part of the management team in setting strategic direction, and structuring and negotiating mission-critical transactions. Her combination of business and legal experience covers the full spectrum of transactions and issues facing Life Sciences and other technology companies.
In 2001, Ms. Kosacz served as the vice president, business development and general counsel of iScribe, Inc., a venture-backed eHealth start up company, where she gained critical operating experience. Her company experience allows her to be especially attuned to the issues emerging company clients face.
Ms. Kosacz has been a speaker at multiple life sciences-related conferences (Allicense; C21 Ventures; BioPartnering Europe; BioPartnering North America; ; BIO Europe; BIO CEO & Investor Conference; BioEquity Europe; BIO Annual Meetings; etc.), as well as guest lecturer from time to time at University of California, Berkeley (Boalt Hall), and Stanford University on biotechnology law, biotech business models, corporate partnering negotiations and deal structures, and bioethics. Ms. Kosacz is listed in The Best Lawyers in America 2008, listed as a leading attorney in the sixth annual Chambers USA: America's Leading Lawyers for Business, listed in Northern California's Super Lawyers from 2004 to 2008, and was selected in 2006 as one of Lawdragon's New Stars, New Worlds.
Ms. Kosacz received a JD from University of California, Berkeley, Boalt Hall School of Law in 1988, where she served as Senior Articles Editor of the High Technology Law Journal (now the Berkeley Technology Law Journal). She received her BA from Stanford University in 1980.
Education- University of California, Berkeley School of Law (Boalt Hall)
JD, 1988 - Stanford University
BA Classics, 1980
Admissions
|